Osteonecrosis mandibular por uso de agentes antirresortivos
The antiresorptive agents-related osteoecrosis of the jaws (ARONJ) is a severe complication in patients receiving medications such as bisphosphonates, denosumab, or antiangiogens. Bisphosphonates and other antiresorptives, such as denosumab, are potent inhibitors of osteoclast function and osteocl...
Guardado en:
| Publicado en: | Revista de la Facultad de Odontología |
|---|---|
| Autores principales: | , , , |
| Materias: | |
| Acceso en línea: | https://bdigital.uncu.edu.ar/fichas.php?idobjeto=16434 |
| Sumario: | The antiresorptive agents-related osteoecrosis of the jaws (ARONJ) is a severe complication in patients receiving medications such as bisphosphonates, denosumab, or antiangiogens.
Bisphosphonates and other antiresorptives, such as denosumab, are potent inhibitors of osteoclast function and osteoclast-mediated bone resorption. They are used effectively to reduce the bone resorption process and improve the quality of life of patients with osteoporosis, malignant osteolytic diseases and other bone lesions such as Paget’s disease or osteogenesis imperfecta 1, 6
We will present a clinical case of a 64-year-old patient, with a history of administration of zolendronate and denosumab, who presents bone exposure in the post-exodontic socket of 1 year of evolution. |
|---|
